Belpointe Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Belpointe Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,241	Closed	-$56.1K	–	1148
2023 Q1	$56.1K	Hold	1,241	–	–	﹤0.01%	1630
2022 Q4	$50.4K	Buy	+1,241	New	+$65.8K	﹤0.01%	1607
2021 Q4	–	Sell	-1,536	Closed	-$173K	–	1209
2021 Q3	$173K	Buy	1,536 +536	+54%	+$67.3K	0.01%	910
2021 Q2	$162K	Sell	1,000 -1,617	-62%	-$197K	0.01%	918
2021 Q1	$319K	Buy	+2,617	New	+$395K	0.03%	580

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Belpointe Asset Management's CRSP Position: Q2 2023 in Review

Belpointe Asset Management sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 1,241 shares — an estimated $56.1K sold.

Belpointe Asset Management first reported a position in CRSP in Q1 2021 and held it in 5 quarters. The position peaked at $319K in Q1 2021. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

Belpointe Asset Management reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 1,241 CRISPR Therapeutics shares in Q2 2023, an estimated $56.1K.
Belpointe Asset Management first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 5 quarters.
Belpointe Asset Management's CRISPR Therapeutics position peaked at $319K in Q1 2021.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.